Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
October 10, 2024 08:07 ET
|
Clearmind Medicine Inc.
FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or...
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
September 16, 2024 16:06 ET
|
Clearmind Medicine Inc.
Innovative drug treatment developed in collaboration with SciSparc aims to enhance safety and efficacy in mental health and addiction care Vancouver, Canada, Sept. 16, 2024 (GLOBE NEWSWIRE) --...
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
September 12, 2024 08:20 ET
|
Clearmind Medicine Inc.
Innovative compounds designed to address critical unmet needs in PTSD treatment Vancouver, Canada, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0)...
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
September 06, 2024 07:55 ET
|
Clearmind Medicine Inc.
Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacyin Mental Health and Addiction Treatments Vancouver, Canada, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq:...
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
August 29, 2024 16:25 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
August 21, 2024 16:11 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
August 16, 2024 16:14 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of...
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
August 06, 2024 08:57 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
July 31, 2024 07:44 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, July 31, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
July 19, 2024 07:55 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, July 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...